[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fak2EPYgIx85Us0-XsOxnltN1tOFeXgDZ_tzF1TpnF0E":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":56,"rows":63},"Albert Einstein College of Medicine",[4],199,false,30,10,213036,7,122,[14,17,20,22,24,26,29,32],{"name":15,"count":16},"Chronic Pain",11,{"name":18,"count":19},"Type 1 Diabetes",8,{"name":21,"count":11},"HIV",{"name":23,"count":11},"Type 2 Diabetes",{"name":25,"count":11},"Pain",{"name":27,"count":28},"Breast Cancer",6,{"name":30,"count":31},"Chronic Kidney Disease",5,{"name":33,"count":34},"Hypertension",4,[36,41,46,51],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04147806","A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer","2026-07","Dexamethasone",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05918029","Bone in CKD Alkali Response (BICARb Pilot Trial)","2026-08","Potassium Citrate Extended Release Oral",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT03540758","Regulation of Endogenous Glucose Production by Central KATP Channels","2027-04","Diazoxide",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT07526948","Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV","2031-06-30","Vaginal estradiol",[57,58,59,60,61,62],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[64,94,118,136,184,207,243,261,292,333,373,402,427,454,472,490,516,534,557,585,603,621,639,664,682,716,753,790,815,840,866,890,908,926,944,984,1014,1051,1076,1105,1123,1141,1159,1177,1204,1222,1240,1258,1284,1302,1320,1338,1364,1382,1407,1425,1450,1473,1502,1524,1556,1574,1592,1616,1634,1657,1683,1701,1728,1750,1768,1795,1813,1831,1860,1878,1915,1938,1964,1982,2011,2029,2047,2065,2088,2109,2139,2157,2175,2193,2211,2234,2258,2288,2306,2324,2419,2453,2479,2507,2533,2555,2583,2615,2654,2677,2695,2713,2731,2757,2781,2799],{"intervention":55,"totalTrials":65,"cells":66},1,{"EARLY_PHASE1":67,"PHASE1":70,"PHASE2":72,"PHASE3":74,"PHASE4":76,"NA":92},{"trials":68,"activeCount":69},[],0,{"trials":71,"activeCount":69},[],{"trials":73,"activeCount":69},[],{"trials":75,"activeCount":69},[],{"trials":77,"activeCount":65,"soonestReadout":54},[78],{"nctId":52,"briefTitle":53,"status":79,"phases":80,"primaryCompletion":54,"completion":54,"start":81,"enrollment":82,"conditions":83,"interventions":91},"NOT_YET_RECRUITING",[61],"2026-06-01",62,[84,85,86,87,88,89,90],"Menopausal Complaints","Vaginal Atrophy","Genitourinary Symptoms","HIV (Human Immunodeficiency Virus)","Menopause Related Conditions","Vaginitis","Perimenopause",[55],{"trials":93,"activeCount":69},[],{"intervention":45,"totalTrials":65,"cells":95},{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":114,"NA":116},{"trials":97,"activeCount":69},[],{"trials":99,"activeCount":69},[],{"trials":101,"activeCount":69},[],{"trials":103,"activeCount":65,"soonestReadout":44},[104],{"nctId":42,"briefTitle":43,"status":105,"phases":106,"primaryCompletion":44,"completion":44,"start":107,"enrollment":108,"conditions":109,"interventions":112},"RECRUITING",[59,60],"2024-08-15",103,[110,111],"Chronic Kidney Diseases","Bone Loss",[45,113],"Potassium Citrate and Citric Acid Oral Solution",{"trials":115,"activeCount":69},[],{"trials":117,"activeCount":69},[],{"intervention":113,"totalTrials":65,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":126,"PHASE4":132,"NA":134},{"trials":121,"activeCount":69},[],{"trials":123,"activeCount":69},[],{"trials":125,"activeCount":69},[],{"trials":127,"activeCount":65,"soonestReadout":44},[128],{"nctId":42,"briefTitle":43,"status":105,"phases":129,"primaryCompletion":44,"completion":44,"start":107,"enrollment":108,"conditions":130,"interventions":131},[59,60],[110,111],[45,113],{"trials":133,"activeCount":69},[],{"trials":135,"activeCount":69},[],{"intervention":50,"totalTrials":137,"cells":138},3,{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":165,"PHASE4":167,"NA":182},{"trials":140,"activeCount":69},[],{"trials":142,"activeCount":69},[],{"trials":144,"activeCount":65,"soonestReadout":49},[145,158],{"nctId":146,"briefTitle":147,"status":148,"phases":149,"primaryCompletion":150,"completion":150,"start":151,"enrollment":69,"conditions":152,"interventions":156},"NCT03685773","The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients","WITHDRAWN",[59],"2023-04-21","2019-04-21",[153,154,155],"Diabetes Mellitus, Type 2","Glucose, High Blood","Glucose Metabolism Disorders",[50,157],"Nicotinic acid",{"nctId":47,"briefTitle":48,"status":105,"phases":159,"primaryCompletion":49,"completion":49,"start":160,"enrollment":161,"conditions":162,"interventions":164},[59],"2018-08-01",100,[163,155],"Diabetes Mellitus",[50,157],{"trials":166,"activeCount":69},[],{"trials":168,"activeCount":69},[169],{"nctId":170,"briefTitle":171,"status":172,"phases":173,"primaryCompletion":174,"completion":174,"start":175,"enrollment":34,"conditions":176,"interventions":180},"NCT03608163","Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)","TERMINATED",[61],"2019-08-22","2019-01-08",[177,178,179],"Diabetes Mellitus, Type 1","Hypoglycemia","Hypoglycemia Unawareness",[181,50],"Naloxone",{"trials":183,"activeCount":69},[],{"intervention":157,"totalTrials":185,"cells":186},2,{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":201,"PHASE4":203,"NA":205},{"trials":188,"activeCount":69},[],{"trials":190,"activeCount":69},[],{"trials":192,"activeCount":65,"soonestReadout":49},[193,197],{"nctId":146,"briefTitle":147,"status":148,"phases":194,"primaryCompletion":150,"completion":150,"start":151,"enrollment":69,"conditions":195,"interventions":196},[59],[153,154,155],[50,157],{"nctId":47,"briefTitle":48,"status":105,"phases":198,"primaryCompletion":49,"completion":49,"start":160,"enrollment":161,"conditions":199,"interventions":200},[59],[163,155],[50,157],{"trials":202,"activeCount":69},[],{"trials":204,"activeCount":69},[],{"trials":206,"activeCount":69},[],{"intervention":40,"totalTrials":185,"cells":208},{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":222,"PHASE3":237,"PHASE4":239,"NA":241},{"trials":210,"activeCount":69},[],{"trials":212,"activeCount":65,"soonestReadout":39},[213],{"nctId":37,"briefTitle":38,"status":214,"phases":215,"primaryCompletion":39,"completion":39,"start":216,"enrollment":217,"conditions":218,"interventions":220},"ACTIVE_NOT_RECRUITING",[58],"2016-08-01",31,[219],"Prostate Cancer",[40,221],"Tamsulosin",{"trials":223,"activeCount":69},[224],{"nctId":225,"briefTitle":226,"status":172,"phases":227,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":233},"NCT03237611","Low Dose Aprepitant for Patients Receiving Carboplatin",[59],"2021-02-11","2018-10-30",15,[232],"Chemotherapy-induced Nausea and Vomiting",[234,235,40,236],"Aprepitant 125 mg","Fosaprepitant 115 MG","Ondansetron 16 MG",{"trials":238,"activeCount":69},[],{"trials":240,"activeCount":69},[],{"trials":242,"activeCount":69},[],{"intervention":221,"totalTrials":65,"cells":244},{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":253,"PHASE3":255,"PHASE4":257,"NA":259},{"trials":246,"activeCount":69},[],{"trials":248,"activeCount":65,"soonestReadout":39},[249],{"nctId":37,"briefTitle":38,"status":214,"phases":250,"primaryCompletion":39,"completion":39,"start":216,"enrollment":217,"conditions":251,"interventions":252},[58],[219],[40,221],{"trials":254,"activeCount":69},[],{"trials":256,"activeCount":69},[],{"trials":258,"activeCount":69},[],{"trials":260,"activeCount":69},[],{"intervention":181,"totalTrials":185,"cells":262},{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":282,"PHASE4":284,"NA":290},{"trials":264,"activeCount":69},[],{"trials":266,"activeCount":69},[],{"trials":268,"activeCount":69},[269],{"nctId":270,"briefTitle":271,"status":172,"phases":272,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":278},"NCT00678145","Mechanisms of Hypoglycemia Associated Autonomic Failure",[59],"2018-08","2008-03",39,[163,178,277],"Autonomic Failure",[279,280,281],"naloxone","Morphine sulfate","Epinephrine",{"trials":283,"activeCount":69},[],{"trials":285,"activeCount":69},[286],{"nctId":170,"briefTitle":171,"status":172,"phases":287,"primaryCompletion":174,"completion":174,"start":175,"enrollment":34,"conditions":288,"interventions":289},[61],[177,178,179],[181,50],{"trials":291,"activeCount":69},[],{"intervention":293,"totalTrials":185,"cells":294},"Normal saline",{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":314,"PHASE4":316,"NA":331},{"trials":296,"activeCount":69},[],{"trials":298,"activeCount":69},[],{"trials":300,"activeCount":69},[301],{"nctId":302,"briefTitle":303,"status":304,"phases":305,"primaryCompletion":306,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":312},"NCT01561378","Cardiac Surgery Neuroprotection Study in Elders","COMPLETED",[59],"2014-10","2012-08",22,[310,311],"Post-operative Cognitive Decline","Post-operative Delirium",[313,293],"Aspart insulin",{"trials":315,"activeCount":69},[],{"trials":317,"activeCount":69},[318],{"nctId":319,"briefTitle":320,"status":148,"phases":321,"primaryCompletion":322,"completion":322,"start":323,"enrollment":69,"conditions":324,"interventions":329},"NCT02644473","Safety of Topical Tranexamic Acid in Total Joint Arthroplasty in High Risk Patients",[61],"2019-01","2016-02",[325,326,327,328],"Pulmonary Embolism","Deep Vein Thrombosis","Stroke","Myocardial Infarction",[330,293],"Tranexamic Acid",{"trials":332,"activeCount":69},[],{"intervention":334,"totalTrials":185,"cells":335},"Insulin",{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":355,"PHASE4":357,"NA":371},{"trials":337,"activeCount":69},[],{"trials":339,"activeCount":69},[],{"trials":341,"activeCount":69},[342],{"nctId":343,"briefTitle":344,"status":304,"phases":345,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":354},"NCT00605696","Early Insulin and Development of ARDS",[59],"2011-12","2013-09","2008-04",18,[351,352,353],"Respiratory Distress Syndrome, Adult","Sepsis","Hyperglycemia",[334],{"trials":356,"activeCount":69},[],{"trials":358,"activeCount":69},[359],{"nctId":360,"briefTitle":361,"status":304,"phases":362,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":368},"NCT01269047","Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia",[61],"2016-08","2016-12","2009-08",37,[18],[369,370,334],"Pramlintide","Exenatide",{"trials":372,"activeCount":69},[],{"intervention":370,"totalTrials":185,"cells":374},{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":381,"PHASE4":383,"NA":400},{"trials":376,"activeCount":69},[],{"trials":378,"activeCount":69},[],{"trials":380,"activeCount":69},[],{"trials":382,"activeCount":69},[],{"trials":384,"activeCount":69},[385,389],{"nctId":360,"briefTitle":361,"status":304,"phases":386,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":387,"interventions":388},[61],[18],[369,370,334],{"nctId":390,"briefTitle":391,"status":304,"phases":392,"primaryCompletion":393,"completion":393,"start":394,"enrollment":395,"conditions":396,"interventions":397},"NCT01269034","New Onset Type 1 Diabetes: Role of Exenatide",[61],"2017-01-31","2010-12",13,[18],[370,398,399],"Rapid and long acting insulin","long acting insulin + rapid acting + 1.25 mcg Exenatide",{"trials":401,"activeCount":69},[],{"intervention":403,"totalTrials":65,"cells":404},"Pioglitazone",{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":411,"PHASE4":413,"NA":425},{"trials":406,"activeCount":69},[],{"trials":408,"activeCount":69},[],{"trials":410,"activeCount":69},[],{"trials":412,"activeCount":69},[],{"trials":414,"activeCount":69},[415],{"nctId":416,"briefTitle":417,"status":304,"phases":418,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":424},"NCT00179400","The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans",[61],"2011-07","2000-12",26,[423],"Type 2 Diabetes Mellitus",[403],{"trials":426,"activeCount":69},[],{"intervention":428,"totalTrials":65,"cells":429},"Buprenorphine",{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":438,"NA":452},{"trials":431,"activeCount":69},[],{"trials":433,"activeCount":69},[],{"trials":435,"activeCount":69},[],{"trials":437,"activeCount":69},[],{"trials":439,"activeCount":69},[440],{"nctId":441,"briefTitle":442,"status":304,"phases":443,"primaryCompletion":444,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":450},"NCT01733693","Neurocognitive Effects of Opiate Agonist Treatment",[61],"2017-06","2013-01",135,[448,21,449],"Opioid-Related Disorders","HIV Infections",[428,451],"Methadone",{"trials":453,"activeCount":69},[],{"intervention":451,"totalTrials":65,"cells":455},{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":464,"NA":470},{"trials":457,"activeCount":69},[],{"trials":459,"activeCount":69},[],{"trials":461,"activeCount":69},[],{"trials":463,"activeCount":69},[],{"trials":465,"activeCount":69},[466],{"nctId":441,"briefTitle":442,"status":304,"phases":467,"primaryCompletion":444,"completion":444,"start":445,"enrollment":446,"conditions":468,"interventions":469},[61],[448,21,449],[428,451],{"trials":471,"activeCount":69},[],{"intervention":369,"totalTrials":65,"cells":473},{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":482,"NA":488},{"trials":475,"activeCount":69},[],{"trials":477,"activeCount":69},[],{"trials":479,"activeCount":69},[],{"trials":481,"activeCount":69},[],{"trials":483,"activeCount":69},[484],{"nctId":360,"briefTitle":361,"status":304,"phases":485,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":486,"interventions":487},[61],[18],[369,370,334],{"trials":489,"activeCount":69},[],{"intervention":491,"totalTrials":65,"cells":492},"Standard clinical care first, followed by standard clinical care and varenicline",{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":497,"PHASE3":499,"PHASE4":501,"NA":514},{"trials":494,"activeCount":69},[],{"trials":496,"activeCount":69},[],{"trials":498,"activeCount":69},[],{"trials":500,"activeCount":69},[],{"trials":502,"activeCount":69},[503],{"nctId":504,"briefTitle":505,"status":304,"phases":506,"primaryCompletion":507,"completion":507,"start":508,"enrollment":11,"conditions":509,"interventions":512},"NCT04595318","Varenicline for Co-occurring Cannabis and Tobacco Use",[61],"2015-07","2015-01",[510,511],"Cannabis Dependence","Tobacco Dependence",[491,513],"Standard clinical care and varenicline first, followed by standard clinical care",{"trials":515,"activeCount":69},[],{"intervention":513,"totalTrials":65,"cells":517},{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":526,"NA":532},{"trials":519,"activeCount":69},[],{"trials":521,"activeCount":69},[],{"trials":523,"activeCount":69},[],{"trials":525,"activeCount":69},[],{"trials":527,"activeCount":69},[528],{"nctId":504,"briefTitle":505,"status":304,"phases":529,"primaryCompletion":507,"completion":507,"start":508,"enrollment":11,"conditions":530,"interventions":531},[61],[510,511],[491,513],{"trials":533,"activeCount":69},[],{"intervention":535,"totalTrials":65,"cells":536},"Sitagliptin",{"EARLY_PHASE1":537,"PHASE1":539,"PHASE2":541,"PHASE3":543,"PHASE4":545,"NA":555},{"trials":538,"activeCount":69},[],{"trials":540,"activeCount":69},[],{"trials":542,"activeCount":69},[],{"trials":544,"activeCount":69},[],{"trials":546,"activeCount":69},[547],{"nctId":548,"briefTitle":549,"status":304,"phases":550,"primaryCompletion":551,"completion":551,"start":552,"enrollment":19,"conditions":553,"interventions":554},"NCT01530178","Sitagliptin Dose Determination Study",[61],"2015-03","2011-11",[177],[535],{"trials":556,"activeCount":69},[],{"intervention":558,"totalTrials":65,"cells":559},"Long-Term Varenicline",{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":583},{"trials":561,"activeCount":69},[],{"trials":563,"activeCount":69},[],{"trials":565,"activeCount":69},[],{"trials":567,"activeCount":69},[],{"trials":569,"activeCount":69},[570],{"nctId":571,"briefTitle":572,"status":304,"phases":573,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":581},"NCT03365362","A Trial of Directly Observed and Long-term Varenicline",[61],"2023-11-14","2024-04-24","2018-10-25",243,[579,580],"Tobacco Use Disorder","Opioid-use Disorder",[558,582],"Short-Term Varenicline",{"trials":584,"activeCount":69},[],{"intervention":582,"totalTrials":65,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":593,"PHASE4":595,"NA":601},{"trials":588,"activeCount":69},[],{"trials":590,"activeCount":69},[],{"trials":592,"activeCount":69},[],{"trials":594,"activeCount":69},[],{"trials":596,"activeCount":69},[597],{"nctId":571,"briefTitle":572,"status":304,"phases":598,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":599,"interventions":600},[61],[579,580],[558,582],{"trials":602,"activeCount":69},[],{"intervention":398,"totalTrials":65,"cells":604},{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":613,"NA":619},{"trials":606,"activeCount":69},[],{"trials":608,"activeCount":69},[],{"trials":610,"activeCount":69},[],{"trials":612,"activeCount":69},[],{"trials":614,"activeCount":69},[615],{"nctId":390,"briefTitle":391,"status":304,"phases":616,"primaryCompletion":393,"completion":393,"start":394,"enrollment":395,"conditions":617,"interventions":618},[61],[18],[370,398,399],{"trials":620,"activeCount":69},[],{"intervention":399,"totalTrials":65,"cells":622},{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":629,"PHASE4":631,"NA":637},{"trials":624,"activeCount":69},[],{"trials":626,"activeCount":69},[],{"trials":628,"activeCount":69},[],{"trials":630,"activeCount":69},[],{"trials":632,"activeCount":69},[633],{"nctId":390,"briefTitle":391,"status":304,"phases":634,"primaryCompletion":393,"completion":393,"start":394,"enrollment":395,"conditions":635,"interventions":636},[61],[18],[370,398,399],{"trials":638,"activeCount":69},[],{"intervention":640,"totalTrials":65,"cells":641},"Metformin",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":662},{"trials":643,"activeCount":69},[],{"trials":645,"activeCount":69},[],{"trials":647,"activeCount":69},[],{"trials":649,"activeCount":69},[],{"trials":651,"activeCount":69},[652],{"nctId":653,"briefTitle":654,"status":304,"phases":655,"primaryCompletion":656,"completion":657,"start":306,"enrollment":658,"conditions":659,"interventions":661},"NCT02432287","Metformin in Longevity Study (MILES).",[61],"2015-09","2017-12",16,[660],"Aging",[640],{"trials":663,"activeCount":69},[],{"intervention":330,"totalTrials":65,"cells":665},{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":672,"PHASE4":674,"NA":680},{"trials":667,"activeCount":69},[],{"trials":669,"activeCount":69},[],{"trials":671,"activeCount":69},[],{"trials":673,"activeCount":69},[],{"trials":675,"activeCount":69},[676],{"nctId":319,"briefTitle":320,"status":148,"phases":677,"primaryCompletion":322,"completion":322,"start":323,"enrollment":69,"conditions":678,"interventions":679},[61],[325,326,327,328],[330,293],{"trials":681,"activeCount":69},[],{"intervention":683,"totalTrials":185,"cells":684},"Sodium bicarbonate",{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":691,"PHASE4":712,"NA":714},{"trials":686,"activeCount":69},[],{"trials":688,"activeCount":69},[],{"trials":690,"activeCount":69},[],{"trials":692,"activeCount":69},[693,702],{"nctId":694,"briefTitle":695,"status":304,"phases":696,"primaryCompletion":363,"completion":363,"start":697,"enrollment":698,"conditions":699,"interventions":701},"NCT01452412","Alkali Therapy in Chronic Kidney Disease",[59,60],"2011-10",149,[30,700],"Metabolic Acidosis",[683],{"nctId":703,"briefTitle":704,"status":304,"phases":705,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":710},"NCT00888290","Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects",[59,60],"2010-05","2009-03",20,[30],[683,711],"Placebos",{"trials":713,"activeCount":69},[],{"trials":715,"activeCount":69},[],{"intervention":717,"totalTrials":185,"cells":718},"Hydromorphone",{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":734,"PHASE4":749,"NA":751},{"trials":720,"activeCount":69},[],{"trials":722,"activeCount":69},[],{"trials":724,"activeCount":69},[725],{"nctId":726,"briefTitle":727,"status":304,"phases":728,"primaryCompletion":729,"completion":730,"start":697,"enrollment":731,"conditions":732,"interventions":733},"NCT01675778","Association Between Body Size and Response to Hydromorphone in ED",[59],"2012-10","2012-12",174,[25],[717],{"trials":735,"activeCount":69},[736],{"nctId":737,"briefTitle":738,"status":304,"phases":739,"primaryCompletion":740,"completion":740,"start":741,"enrollment":742,"conditions":743,"interventions":745},"NCT03553498","IV Acetaminophen as Adjuvant Analgesic to Hydromorphone - Emergency Department Patients",[60],"2019-05-15","2018-11-27",162,[744],"Acute Pain",[746,747,748],"IV acetaminophen","IV placebo","hydromorphone",{"trials":750,"activeCount":69},[],{"trials":752,"activeCount":69},[],{"intervention":754,"totalTrials":185,"cells":755},"Vitamin D",{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":773,"PHASE4":786,"NA":788},{"trials":757,"activeCount":69},[],{"trials":759,"activeCount":69},[],{"trials":761,"activeCount":69},[762],{"nctId":763,"briefTitle":764,"status":304,"phases":765,"primaryCompletion":766,"completion":767,"start":768,"enrollment":769,"conditions":770,"interventions":772},"NCT01354964","Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation",[59],"2015-06-03","2015-09-03","2009-03-13",19,[771],"Insulin Resistance",[754],{"trials":774,"activeCount":69},[775],{"nctId":776,"briefTitle":777,"status":304,"phases":778,"primaryCompletion":779,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":785},"NCT01029002","The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease",[60],"2014-06","2009-10",74,[783,784],"Chronic Renal Insufficiency","Proteinuria",[754],{"trials":787,"activeCount":69},[],{"trials":789,"activeCount":69},[],{"intervention":791,"totalTrials":65,"cells":792},"Thyroxine",{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":799,"PHASE4":811,"NA":813},{"trials":794,"activeCount":69},[],{"trials":796,"activeCount":69},[],{"trials":798,"activeCount":69},[],{"trials":800,"activeCount":69},[801],{"nctId":802,"briefTitle":803,"status":148,"phases":804,"primaryCompletion":805,"completion":806,"start":807,"enrollment":69,"conditions":808,"interventions":810},"NCT03390530","Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage",[60],"2025-12-18","2027-01-18","2022-01-18",[809],"Intraventricular Hemorrhage of Prematurity",[791],{"trials":812,"activeCount":69},[],{"trials":814,"activeCount":69},[],{"intervention":816,"totalTrials":65,"cells":817},"Omega-3 Fatty acids",{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":824,"PHASE4":836,"NA":838},{"trials":819,"activeCount":69},[],{"trials":821,"activeCount":69},[],{"trials":823,"activeCount":69},[],{"trials":825,"activeCount":69},[826],{"nctId":827,"briefTitle":828,"status":304,"phases":829,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":833,"interventions":835},"NCT02757872","Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives",[60],"2022-03-31","2016-04",2232,[33,834],"Kidney Diseases",[816],{"trials":837,"activeCount":69},[],{"trials":839,"activeCount":69},[],{"intervention":841,"totalTrials":65,"cells":842},"Ivermectin",{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":862,"NA":864},{"trials":844,"activeCount":69},[],{"trials":846,"activeCount":69},[],{"trials":848,"activeCount":69},[],{"trials":850,"activeCount":69},[851],{"nctId":852,"briefTitle":853,"status":172,"phases":854,"primaryCompletion":855,"completion":855,"start":856,"enrollment":857,"conditions":858,"interventions":861},"NCT03605758","Treatment of Strongyloides Infection",[60],"2015-02-05","2012-05",51,[859,860],"Strongyloides Stercoralis Infection","Strongyloidiasis",[841],{"trials":863,"activeCount":69},[],{"trials":865,"activeCount":69},[],{"intervention":867,"totalTrials":65,"cells":868},"Chemotherapy drug",{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":886,"NA":888},{"trials":870,"activeCount":69},[],{"trials":872,"activeCount":69},[],{"trials":874,"activeCount":69},[],{"trials":876,"activeCount":69},[877],{"nctId":878,"briefTitle":879,"status":172,"phases":880,"primaryCompletion":881,"completion":881,"start":882,"enrollment":31,"conditions":883,"interventions":885},"NCT04592861","Carbon Ion RT for Locally Advanced Pancreatic Cancer",[60],"2022-08-24","2020-11-01",[884],"Pancreatic Cancer",[867],{"trials":887,"activeCount":69},[],{"trials":889,"activeCount":69},[],{"intervention":711,"totalTrials":65,"cells":891},{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":898,"PHASE4":904,"NA":906},{"trials":893,"activeCount":69},[],{"trials":895,"activeCount":69},[],{"trials":897,"activeCount":69},[],{"trials":899,"activeCount":69},[900],{"nctId":703,"briefTitle":704,"status":304,"phases":901,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":902,"interventions":903},[59,60],[30],[683,711],{"trials":905,"activeCount":69},[],{"trials":907,"activeCount":69},[],{"intervention":746,"totalTrials":65,"cells":909},{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":922,"NA":924},{"trials":911,"activeCount":69},[],{"trials":913,"activeCount":69},[],{"trials":915,"activeCount":69},[],{"trials":917,"activeCount":69},[918],{"nctId":737,"briefTitle":738,"status":304,"phases":919,"primaryCompletion":740,"completion":740,"start":741,"enrollment":742,"conditions":920,"interventions":921},[60],[744],[746,747,748],{"trials":923,"activeCount":69},[],{"trials":925,"activeCount":69},[],{"intervention":747,"totalTrials":65,"cells":927},{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":934,"PHASE4":940,"NA":942},{"trials":929,"activeCount":69},[],{"trials":931,"activeCount":69},[],{"trials":933,"activeCount":69},[],{"trials":935,"activeCount":69},[936],{"nctId":737,"briefTitle":738,"status":304,"phases":937,"primaryCompletion":740,"completion":740,"start":741,"enrollment":742,"conditions":938,"interventions":939},[60],[744],[746,747,748],{"trials":941,"activeCount":69},[],{"trials":943,"activeCount":69},[],{"intervention":945,"totalTrials":185,"cells":946},"Erlotinib Hydrochloride",{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":948,"activeCount":69},[],{"trials":950,"activeCount":69},[],{"trials":952,"activeCount":69},[953,969],{"nctId":954,"briefTitle":955,"status":304,"phases":956,"primaryCompletion":957,"completion":957,"start":958,"enrollment":959,"conditions":960,"interventions":967},"NCT00950365","Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer",[59],"2017-11-17","2006-04",79,[961,962,963,964,965,966],"Bronchioloalveolar Carcinoma","Large Cell Lung Carcinoma","Lung Adenocarcinoma","Recurrent Non-Small Cell Lung Carcinoma","Stage IIIB Non-Small Cell Lung Cancer","Stage IV Non-Small Cell Lung Cancer",[945,968],"Pemetrexed Disodium",{"nctId":970,"briefTitle":971,"status":172,"phases":972,"primaryCompletion":973,"completion":973,"start":974,"enrollment":137,"conditions":975,"interventions":977},"NCT01857271","Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer",[59],"2017-08-31","2013-11",[976,965],"Stage IIIA Non-Small Cell Lung Cancer",[945],{"trials":979,"activeCount":69},[],{"trials":981,"activeCount":69},[],{"trials":983,"activeCount":69},[],{"intervention":968,"totalTrials":185,"cells":985},{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":1008,"PHASE4":1010,"NA":1012},{"trials":987,"activeCount":69},[],{"trials":989,"activeCount":69},[],{"trials":991,"activeCount":69},[992,996],{"nctId":954,"briefTitle":955,"status":304,"phases":993,"primaryCompletion":957,"completion":957,"start":958,"enrollment":959,"conditions":994,"interventions":995},[59],[961,962,963,964,965,966],[945,968],{"nctId":997,"briefTitle":998,"status":304,"phases":999,"primaryCompletion":508,"completion":1000,"start":1001,"enrollment":308,"conditions":1002,"interventions":1006},"NCT01001910","Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[59],"2015-02","2008-07",[1003,1004,1005],"Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma",[1007,968],"Carboplatin",{"trials":1009,"activeCount":69},[],{"trials":1011,"activeCount":69},[],{"trials":1013,"activeCount":69},[],{"intervention":1015,"totalTrials":185,"cells":1016},"Lenalidomide",{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1045,"PHASE4":1047,"NA":1049},{"trials":1018,"activeCount":69},[],{"trials":1020,"activeCount":69},[],{"trials":1022,"activeCount":69},[1023,1033],{"nctId":1024,"briefTitle":1025,"status":172,"phases":1026,"primaryCompletion":508,"completion":1027,"start":1028,"enrollment":137,"conditions":1029,"interventions":1032},"NCT02038153","Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant",[58,59],"2016-01","2013-12",[1030,1031],"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Adult Acute Myeloid Leukemia in Remission",[1015],{"nctId":1034,"briefTitle":1035,"status":304,"phases":1036,"primaryCompletion":1037,"completion":1037,"start":729,"enrollment":1038,"conditions":1039,"interventions":1043},"NCT01772420","Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia",[59],"2020-07-09",52,[1040,1041,1042],"Adult Myelodysplastic Syndrome","Anemia","Chronic Myelomonocytic Leukemia",[1044,1015],"Eltrombopag Olamine",{"trials":1046,"activeCount":69},[],{"trials":1048,"activeCount":69},[],{"trials":1050,"activeCount":69},[],{"intervention":1052,"totalTrials":65,"cells":1053},"Cannabis",{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1058,"PHASE3":1070,"PHASE4":1072,"NA":1074},{"trials":1055,"activeCount":69},[],{"trials":1057,"activeCount":69},[],{"trials":1059,"activeCount":69},[1060],{"nctId":1061,"briefTitle":1062,"status":304,"phases":1063,"primaryCompletion":1064,"completion":1064,"start":1065,"enrollment":1066,"conditions":1067,"interventions":1069},"NCT03633721","Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women",[59],"2022-05-31","2020-10-23",25,[21,1068,660],"AIDS",[1052],{"trials":1071,"activeCount":69},[],{"trials":1073,"activeCount":69},[],{"trials":1075,"activeCount":69},[],{"intervention":1077,"totalTrials":65,"cells":1078},"oxycodone\u002FAPAP",{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1099,"PHASE4":1101,"NA":1103},{"trials":1080,"activeCount":69},[],{"trials":1082,"activeCount":69},[],{"trials":1084,"activeCount":69},[1085],{"nctId":1086,"briefTitle":1087,"status":304,"phases":1088,"primaryCompletion":1089,"completion":1089,"start":1090,"enrollment":1091,"conditions":1092,"interventions":1094},"NCT03173456","Comparing Five Oral Analgesics for Treatment of Acute Pain in the Emergency Department (ED)",[59],"2019-11-14","2017-11-28",600,[1093],"Musculoskeletal Pain",[1077,1095,1096,1097,1098],"hydrocodone\u002FAPAP","codeine\u002FAPAP","400 ibuprofen\u002FAPAP","800 ibuprofen\u002FAPAP",{"trials":1100,"activeCount":69},[],{"trials":1102,"activeCount":69},[],{"trials":1104,"activeCount":69},[],{"intervention":1095,"totalTrials":65,"cells":1106},{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1117,"PHASE4":1119,"NA":1121},{"trials":1108,"activeCount":69},[],{"trials":1110,"activeCount":69},[],{"trials":1112,"activeCount":69},[1113],{"nctId":1086,"briefTitle":1087,"status":304,"phases":1114,"primaryCompletion":1089,"completion":1089,"start":1090,"enrollment":1091,"conditions":1115,"interventions":1116},[59],[1093],[1077,1095,1096,1097,1098],{"trials":1118,"activeCount":69},[],{"trials":1120,"activeCount":69},[],{"trials":1122,"activeCount":69},[],{"intervention":1096,"totalTrials":65,"cells":1124},{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1135,"PHASE4":1137,"NA":1139},{"trials":1126,"activeCount":69},[],{"trials":1128,"activeCount":69},[],{"trials":1130,"activeCount":69},[1131],{"nctId":1086,"briefTitle":1087,"status":304,"phases":1132,"primaryCompletion":1089,"completion":1089,"start":1090,"enrollment":1091,"conditions":1133,"interventions":1134},[59],[1093],[1077,1095,1096,1097,1098],{"trials":1136,"activeCount":69},[],{"trials":1138,"activeCount":69},[],{"trials":1140,"activeCount":69},[],{"intervention":1097,"totalTrials":65,"cells":1142},{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1153,"PHASE4":1155,"NA":1157},{"trials":1144,"activeCount":69},[],{"trials":1146,"activeCount":69},[],{"trials":1148,"activeCount":69},[1149],{"nctId":1086,"briefTitle":1087,"status":304,"phases":1150,"primaryCompletion":1089,"completion":1089,"start":1090,"enrollment":1091,"conditions":1151,"interventions":1152},[59],[1093],[1077,1095,1096,1097,1098],{"trials":1154,"activeCount":69},[],{"trials":1156,"activeCount":69},[],{"trials":1158,"activeCount":69},[],{"intervention":1098,"totalTrials":65,"cells":1160},{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1171,"PHASE4":1173,"NA":1175},{"trials":1162,"activeCount":69},[],{"trials":1164,"activeCount":69},[],{"trials":1166,"activeCount":69},[1167],{"nctId":1086,"briefTitle":1087,"status":304,"phases":1168,"primaryCompletion":1089,"completion":1089,"start":1090,"enrollment":1091,"conditions":1169,"interventions":1170},[59],[1093],[1077,1095,1096,1097,1098],{"trials":1172,"activeCount":69},[],{"trials":1174,"activeCount":69},[],{"trials":1176,"activeCount":69},[],{"intervention":1178,"totalTrials":65,"cells":1179},"Sirolimus 2mg",{"EARLY_PHASE1":1180,"PHASE1":1182,"PHASE2":1184,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1181,"activeCount":69},[],{"trials":1183,"activeCount":69},[],{"trials":1185,"activeCount":69},[1186],{"nctId":1187,"briefTitle":1188,"status":172,"phases":1189,"primaryCompletion":1190,"completion":1190,"start":1191,"enrollment":28,"conditions":1192,"interventions":1197},"NCT04393454","Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy",[59],"2023-05-16","2020-11-16",[1193,1194,1195,1196],"Metastatic dMMR Solid Cancer","Solid Tumor","Cancer","Metastatic Solid Tumor",[1178],{"trials":1199,"activeCount":69},[],{"trials":1201,"activeCount":69},[],{"trials":1203,"activeCount":69},[],{"intervention":234,"totalTrials":65,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1207,"activeCount":69},[],{"trials":1209,"activeCount":69},[],{"trials":1211,"activeCount":69},[1212],{"nctId":225,"briefTitle":226,"status":172,"phases":1213,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":1214,"interventions":1215},[59],[232],[234,235,40,236],{"trials":1217,"activeCount":69},[],{"trials":1219,"activeCount":69},[],{"trials":1221,"activeCount":69},[],{"intervention":235,"totalTrials":65,"cells":1223},{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1225,"activeCount":69},[],{"trials":1227,"activeCount":69},[],{"trials":1229,"activeCount":69},[1230],{"nctId":225,"briefTitle":226,"status":172,"phases":1231,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":1232,"interventions":1233},[59],[232],[234,235,40,236],{"trials":1235,"activeCount":69},[],{"trials":1237,"activeCount":69},[],{"trials":1239,"activeCount":69},[],{"intervention":236,"totalTrials":65,"cells":1241},{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1246,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1243,"activeCount":69},[],{"trials":1245,"activeCount":69},[],{"trials":1247,"activeCount":69},[1248],{"nctId":225,"briefTitle":226,"status":172,"phases":1249,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":1250,"interventions":1251},[59],[232],[234,235,40,236],{"trials":1253,"activeCount":69},[],{"trials":1255,"activeCount":69},[],{"trials":1257,"activeCount":69},[],{"intervention":1259,"totalTrials":65,"cells":1260},"HspE7",{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1278,"PHASE4":1280,"NA":1282},{"trials":1262,"activeCount":69},[],{"trials":1264,"activeCount":69},[],{"trials":1266,"activeCount":69},[1267],{"nctId":1268,"briefTitle":1269,"status":304,"phases":1270,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":1273,"conditions":1274,"interventions":1277},"NCT00075569","SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia",[59],"2005-08","2004-03",64,[1275,1276],"Cervical Cancer","Precancerous Condition",[1259],{"trials":1279,"activeCount":69},[],{"trials":1281,"activeCount":69},[],{"trials":1283,"activeCount":69},[],{"intervention":313,"totalTrials":65,"cells":1285},{"EARLY_PHASE1":1286,"PHASE1":1288,"PHASE2":1290,"PHASE3":1296,"PHASE4":1298,"NA":1300},{"trials":1287,"activeCount":69},[],{"trials":1289,"activeCount":69},[],{"trials":1291,"activeCount":69},[1292],{"nctId":302,"briefTitle":303,"status":304,"phases":1293,"primaryCompletion":306,"completion":306,"start":307,"enrollment":308,"conditions":1294,"interventions":1295},[59],[310,311],[313,293],{"trials":1297,"activeCount":69},[],{"trials":1299,"activeCount":69},[],{"trials":1301,"activeCount":69},[],{"intervention":280,"totalTrials":65,"cells":1303},{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1305,"activeCount":69},[],{"trials":1307,"activeCount":69},[],{"trials":1309,"activeCount":69},[1310],{"nctId":270,"briefTitle":271,"status":172,"phases":1311,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":1312,"interventions":1313},[59],[163,178,277],[279,280,281],{"trials":1315,"activeCount":69},[],{"trials":1317,"activeCount":69},[],{"trials":1319,"activeCount":69},[],{"intervention":281,"totalTrials":65,"cells":1321},{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1332,"PHASE4":1334,"NA":1336},{"trials":1323,"activeCount":69},[],{"trials":1325,"activeCount":69},[],{"trials":1327,"activeCount":69},[1328],{"nctId":270,"briefTitle":271,"status":172,"phases":1329,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":1330,"interventions":1331},[59],[163,178,277],[279,280,281],{"trials":1333,"activeCount":69},[],{"trials":1335,"activeCount":69},[],{"trials":1337,"activeCount":69},[],{"intervention":1339,"totalTrials":65,"cells":1340},"PET-based, dose-painted, accelerated chemoradiotherapy",{"EARLY_PHASE1":1341,"PHASE1":1343,"PHASE2":1345,"PHASE3":1358,"PHASE4":1360,"NA":1362},{"trials":1342,"activeCount":69},[],{"trials":1344,"activeCount":69},[],{"trials":1346,"activeCount":69},[1347],{"nctId":1348,"briefTitle":1349,"status":304,"phases":1350,"primaryCompletion":1351,"completion":1351,"start":1352,"enrollment":1353,"conditions":1354,"interventions":1356},"NCT03481114","Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer",[59],"2023-12-27","2017-08-28",55,[1355],"Non-small Cell Lung Cancer",[1339,1357],"Standard chemoradiotherapy",{"trials":1359,"activeCount":69},[],{"trials":1361,"activeCount":69},[],{"trials":1363,"activeCount":69},[],{"intervention":1357,"totalTrials":65,"cells":1365},{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1376,"PHASE4":1378,"NA":1380},{"trials":1367,"activeCount":69},[],{"trials":1369,"activeCount":69},[],{"trials":1371,"activeCount":69},[1372],{"nctId":1348,"briefTitle":1349,"status":304,"phases":1373,"primaryCompletion":1351,"completion":1351,"start":1352,"enrollment":1353,"conditions":1374,"interventions":1375},[59],[1355],[1339,1357],{"trials":1377,"activeCount":69},[],{"trials":1379,"activeCount":69},[],{"trials":1381,"activeCount":69},[],{"intervention":1383,"totalTrials":65,"cells":1384},"Gemcitabine",{"EARLY_PHASE1":1385,"PHASE1":1387,"PHASE2":1389,"PHASE3":1401,"PHASE4":1403,"NA":1405},{"trials":1386,"activeCount":69},[],{"trials":1388,"activeCount":69},[],{"trials":1390,"activeCount":69},[1391],{"nctId":1392,"briefTitle":1393,"status":172,"phases":1394,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":9,"conditions":1398,"interventions":1399},"NCT03848182","Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer",[59],"2018-11-23","2019-11-11","2017-07-21",[884],[1383,1400],"TT vaccine booster",{"trials":1402,"activeCount":69},[],{"trials":1404,"activeCount":69},[],{"trials":1406,"activeCount":69},[],{"intervention":1400,"totalTrials":65,"cells":1408},{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1419,"PHASE4":1421,"NA":1423},{"trials":1410,"activeCount":69},[],{"trials":1412,"activeCount":69},[],{"trials":1414,"activeCount":69},[1415],{"nctId":1392,"briefTitle":1393,"status":172,"phases":1416,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":9,"conditions":1417,"interventions":1418},[59],[884],[1383,1400],{"trials":1420,"activeCount":69},[],{"trials":1422,"activeCount":69},[],{"trials":1424,"activeCount":69},[],{"intervention":1426,"totalTrials":65,"cells":1427},"Immune Globulin Intravenous",{"EARLY_PHASE1":1428,"PHASE1":1430,"PHASE2":1432,"PHASE3":1444,"PHASE4":1446,"NA":1448},{"trials":1429,"activeCount":69},[],{"trials":1431,"activeCount":69},[],{"trials":1433,"activeCount":69},[1434],{"nctId":1435,"briefTitle":1436,"status":304,"phases":1437,"primaryCompletion":1438,"completion":1438,"start":1439,"enrollment":1440,"conditions":1441,"interventions":1443},"NCT01757418","Intravenous Gammaglobulin for Sickle Cell Pain Crises",[58,59],"2024-12-18","2008-11",300,[1442,25],"Sickle Cell Disease",[1426],{"trials":1445,"activeCount":69},[],{"trials":1447,"activeCount":69},[],{"trials":1449,"activeCount":69},[],{"intervention":1451,"totalTrials":65,"cells":1452},"arsenic trioxide",{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1457,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1454,"activeCount":69},[],{"trials":1456,"activeCount":69},[],{"trials":1458,"activeCount":69},[1459],{"nctId":1460,"briefTitle":1461,"status":304,"phases":1462,"primaryCompletion":1463,"completion":1463,"start":1464,"enrollment":366,"conditions":1465,"interventions":1466},"NCT00004149","Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy",[59],"2003-08","1999-09",[219],[1451],{"trials":1468,"activeCount":69},[],{"trials":1470,"activeCount":69},[],{"trials":1472,"activeCount":69},[],{"intervention":1474,"totalTrials":65,"cells":1475},"Mitomycin C",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1496,"PHASE4":1498,"NA":1500},{"trials":1477,"activeCount":69},[],{"trials":1479,"activeCount":69},[],{"trials":1481,"activeCount":69},[1482],{"nctId":1483,"briefTitle":1484,"status":304,"phases":1485,"primaryCompletion":1486,"completion":1487,"start":552,"enrollment":857,"conditions":1488,"interventions":1495},"NCT02040142","HIPEC for Peritoneal Carcinomatosis",[59],"2022-10-13","2024-08-19",[1489,1490,1491,1492,1493,1494],"Peritoneal Carcinomatosis","Colorectal Cancer","Appendiceal Cancer","Peritoneal Mesothelioma","Pseudomyxoma Peritonei","Gastric Cancer",[1474],{"trials":1497,"activeCount":69},[],{"trials":1499,"activeCount":69},[],{"trials":1501,"activeCount":69},[],{"intervention":1503,"totalTrials":65,"cells":1504},"Resveratrol",{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1518,"PHASE4":1520,"NA":1522},{"trials":1506,"activeCount":69},[],{"trials":1508,"activeCount":69},[],{"trials":1510,"activeCount":69},[1511],{"nctId":1512,"briefTitle":1513,"status":304,"phases":1514,"primaryCompletion":1515,"completion":1515,"start":274,"enrollment":708,"conditions":1516,"interventions":1517},"NCT01354977","Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans",[59],"2017-09-15",[423,771],[1503],{"trials":1519,"activeCount":69},[],{"trials":1521,"activeCount":69},[],{"trials":1523,"activeCount":69},[],{"intervention":1525,"totalTrials":65,"cells":1526},"Fluorouracil",{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1550,"PHASE4":1552,"NA":1554},{"trials":1528,"activeCount":69},[],{"trials":1530,"activeCount":69},[],{"trials":1532,"activeCount":69},[1533],{"nctId":1534,"briefTitle":1535,"status":172,"phases":1536,"primaryCompletion":1537,"completion":1537,"start":1538,"enrollment":1539,"conditions":1540,"interventions":1545},"NCT01897454","Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer",[59],"2021-11-01","2012-01-27",23,[1541,1542,1543,1544],"Pancreatic Adenocarcinoma","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer","Stage III Pancreatic Cancer",[1525,1546,1547,1548,1549],"Gemcitabine Hydrochloride","Irinotecan Hydrochloride","Leucovorin Calcium","Oxaliplatin",{"trials":1551,"activeCount":69},[],{"trials":1553,"activeCount":69},[],{"trials":1555,"activeCount":69},[],{"intervention":1547,"totalTrials":65,"cells":1557},{"EARLY_PHASE1":1558,"PHASE1":1560,"PHASE2":1562,"PHASE3":1568,"PHASE4":1570,"NA":1572},{"trials":1559,"activeCount":69},[],{"trials":1561,"activeCount":69},[],{"trials":1563,"activeCount":69},[1564],{"nctId":1534,"briefTitle":1535,"status":172,"phases":1565,"primaryCompletion":1537,"completion":1537,"start":1538,"enrollment":1539,"conditions":1566,"interventions":1567},[59],[1541,1542,1543,1544],[1525,1546,1547,1548,1549],{"trials":1569,"activeCount":69},[],{"trials":1571,"activeCount":69},[],{"trials":1573,"activeCount":69},[],{"intervention":1548,"totalTrials":65,"cells":1575},{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1586,"PHASE4":1588,"NA":1590},{"trials":1577,"activeCount":69},[],{"trials":1579,"activeCount":69},[],{"trials":1581,"activeCount":69},[1582],{"nctId":1534,"briefTitle":1535,"status":172,"phases":1583,"primaryCompletion":1537,"completion":1537,"start":1538,"enrollment":1539,"conditions":1584,"interventions":1585},[59],[1541,1542,1543,1544],[1525,1546,1547,1548,1549],{"trials":1587,"activeCount":69},[],{"trials":1589,"activeCount":69},[],{"trials":1591,"activeCount":69},[],{"intervention":1593,"totalTrials":65,"cells":1594},"Lidocaine Hydrochloride",{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1610,"PHASE4":1612,"NA":1614},{"trials":1596,"activeCount":69},[],{"trials":1598,"activeCount":69},[],{"trials":1600,"activeCount":69},[1601],{"nctId":1602,"briefTitle":1603,"status":148,"phases":1604,"primaryCompletion":1605,"completion":1605,"start":1606,"enrollment":69,"conditions":1607,"interventions":1608},"NCT03787147","Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI)",[59],"2020-12-01","2020-11-30",[25],[1593,1609],"Bupivacaine",{"trials":1611,"activeCount":69},[],{"trials":1613,"activeCount":69},[],{"trials":1615,"activeCount":69},[],{"intervention":1609,"totalTrials":65,"cells":1617},{"EARLY_PHASE1":1618,"PHASE1":1620,"PHASE2":1622,"PHASE3":1628,"PHASE4":1630,"NA":1632},{"trials":1619,"activeCount":69},[],{"trials":1621,"activeCount":69},[],{"trials":1623,"activeCount":69},[1624],{"nctId":1602,"briefTitle":1603,"status":148,"phases":1625,"primaryCompletion":1605,"completion":1605,"start":1606,"enrollment":69,"conditions":1626,"interventions":1627},[59],[25],[1593,1609],{"trials":1629,"activeCount":69},[],{"trials":1631,"activeCount":69},[],{"trials":1633,"activeCount":69},[],{"intervention":1635,"totalTrials":65,"cells":1636},"glucagon like peptide-1",{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1641,"PHASE3":1651,"PHASE4":1653,"NA":1655},{"trials":1638,"activeCount":69},[],{"trials":1640,"activeCount":69},[],{"trials":1642,"activeCount":69},[1643],{"nctId":1644,"briefTitle":1645,"status":172,"phases":1646,"primaryCompletion":1647,"completion":1647,"start":1648,"enrollment":708,"conditions":1649,"interventions":1650},"NCT00609154","Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates",[58,59],"2014-05-13","2010-08-12",[23],[1635],{"trials":1652,"activeCount":69},[],{"trials":1654,"activeCount":69},[],{"trials":1656,"activeCount":69},[],{"intervention":1658,"totalTrials":65,"cells":1659},"FLT3 Ligand",{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1677,"PHASE4":1679,"NA":1681},{"trials":1661,"activeCount":69},[],{"trials":1663,"activeCount":69},[],{"trials":1665,"activeCount":69},[1666],{"nctId":1667,"briefTitle":1668,"status":172,"phases":1669,"primaryCompletion":1670,"completion":1670,"start":1671,"enrollment":31,"conditions":1672,"interventions":1675},"NCT04491084","FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy",[58,59],"2022-08-18","2021-01-01",[1673,1674],"Non Small Cell Lung Cancer","Lung Cancer",[1658,1676],"anti-CD40 antibody",{"trials":1678,"activeCount":69},[],{"trials":1680,"activeCount":69},[],{"trials":1682,"activeCount":69},[],{"intervention":1676,"totalTrials":65,"cells":1684},{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1695,"PHASE4":1697,"NA":1699},{"trials":1686,"activeCount":69},[],{"trials":1688,"activeCount":69},[],{"trials":1690,"activeCount":69},[1691],{"nctId":1667,"briefTitle":1668,"status":172,"phases":1692,"primaryCompletion":1670,"completion":1670,"start":1671,"enrollment":31,"conditions":1693,"interventions":1694},[58,59],[1673,1674],[1658,1676],{"trials":1696,"activeCount":69},[],{"trials":1698,"activeCount":69},[],{"trials":1700,"activeCount":69},[],{"intervention":1702,"totalTrials":65,"cells":1703},"Allergen extracts",{"EARLY_PHASE1":1704,"PHASE1":1706,"PHASE2":1708,"PHASE3":1722,"PHASE4":1724,"NA":1726},{"trials":1705,"activeCount":69},[],{"trials":1707,"activeCount":69},[],{"trials":1709,"activeCount":69},[1710],{"nctId":1711,"briefTitle":1712,"status":304,"phases":1713,"primaryCompletion":1714,"completion":1714,"start":1715,"enrollment":1716,"conditions":1717,"interventions":1721},"NCT01028560","Allergy Immunotherapy for the Reduction of Asthma",[58,59],"2015-04","2008-10",58,[1718,1719,1720],"Wheezing","Asthma","Allergy",[1702],{"trials":1723,"activeCount":69},[],{"trials":1725,"activeCount":69},[],{"trials":1727,"activeCount":69},[],{"intervention":1729,"totalTrials":65,"cells":1730},"Closed loop with sensor and Insulin",{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1735,"PHASE3":1744,"PHASE4":1746,"NA":1748},{"trials":1732,"activeCount":69},[],{"trials":1734,"activeCount":69},[],{"trials":1736,"activeCount":69},[1737],{"nctId":1738,"briefTitle":1739,"status":304,"phases":1740,"primaryCompletion":508,"completion":508,"start":445,"enrollment":349,"conditions":1741,"interventions":1742},"NCT01755416","Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting",[59],[18],[1729,1743],"Closed loop with sensor, Insulin and Liraglutide",{"trials":1745,"activeCount":69},[],{"trials":1747,"activeCount":69},[],{"trials":1749,"activeCount":69},[],{"intervention":1743,"totalTrials":65,"cells":1751},{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1762,"PHASE4":1764,"NA":1766},{"trials":1753,"activeCount":69},[],{"trials":1755,"activeCount":69},[],{"trials":1757,"activeCount":69},[1758],{"nctId":1738,"briefTitle":1739,"status":304,"phases":1759,"primaryCompletion":508,"completion":508,"start":445,"enrollment":349,"conditions":1760,"interventions":1761},[59],[18],[1729,1743],{"trials":1763,"activeCount":69},[],{"trials":1765,"activeCount":69},[],{"trials":1767,"activeCount":69},[],{"intervention":1769,"totalTrials":65,"cells":1770},"Vorinostat",{"EARLY_PHASE1":1771,"PHASE1":1773,"PHASE2":1775,"PHASE3":1789,"PHASE4":1791,"NA":1793},{"trials":1772,"activeCount":69},[],{"trials":1774,"activeCount":69},[],{"trials":1776,"activeCount":69},[1777],{"nctId":1778,"briefTitle":1779,"status":304,"phases":1780,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":1353,"conditions":1783,"interventions":1784},"NCT00574587","Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy",[58,59],"2014-05","2007-12",[27],[1769,1785,1786,1787,1788],"Paclitaxel","Trastuzumab","Doxorubicin","Cyclophosphamide",{"trials":1790,"activeCount":69},[],{"trials":1792,"activeCount":69},[],{"trials":1794,"activeCount":69},[],{"intervention":1787,"totalTrials":65,"cells":1796},{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1807,"PHASE4":1809,"NA":1811},{"trials":1798,"activeCount":69},[],{"trials":1800,"activeCount":69},[],{"trials":1802,"activeCount":69},[1803],{"nctId":1778,"briefTitle":1779,"status":304,"phases":1804,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":1353,"conditions":1805,"interventions":1806},[58,59],[27],[1769,1785,1786,1787,1788],{"trials":1808,"activeCount":69},[],{"trials":1810,"activeCount":69},[],{"trials":1812,"activeCount":69},[],{"intervention":1044,"totalTrials":65,"cells":1814},{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1819,"PHASE3":1825,"PHASE4":1827,"NA":1829},{"trials":1816,"activeCount":69},[],{"trials":1818,"activeCount":69},[],{"trials":1820,"activeCount":69},[1821],{"nctId":1034,"briefTitle":1035,"status":304,"phases":1822,"primaryCompletion":1037,"completion":1037,"start":729,"enrollment":1038,"conditions":1823,"interventions":1824},[59],[1040,1041,1042],[1044,1015],{"trials":1826,"activeCount":69},[],{"trials":1828,"activeCount":69},[],{"trials":1830,"activeCount":69},[],{"intervention":1832,"totalTrials":65,"cells":1833},"Busulfan",{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1854,"PHASE4":1856,"NA":1858},{"trials":1835,"activeCount":69},[],{"trials":1837,"activeCount":69},[],{"trials":1839,"activeCount":69},[1840],{"nctId":1841,"briefTitle":1842,"status":304,"phases":1843,"primaryCompletion":1844,"completion":1844,"start":1845,"enrollment":769,"conditions":1846,"interventions":1851},"NCT01605032","Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma",[59],"2018-03","2012-02",[1847,1848,1849,1850],"DS Stage I Plasma Cell Myeloma","DS Stage II Plasma Cell Myeloma","DS Stage III Plasma Cell Myeloma","Refractory Plasma Cell Myeloma",[1832,1852,1853],"Melphalan","Bortezomib",{"trials":1855,"activeCount":69},[],{"trials":1857,"activeCount":69},[],{"trials":1859,"activeCount":69},[],{"intervention":1853,"totalTrials":65,"cells":1861},{"EARLY_PHASE1":1862,"PHASE1":1864,"PHASE2":1866,"PHASE3":1872,"PHASE4":1874,"NA":1876},{"trials":1863,"activeCount":69},[],{"trials":1865,"activeCount":69},[],{"trials":1867,"activeCount":69},[1868],{"nctId":1841,"briefTitle":1842,"status":304,"phases":1869,"primaryCompletion":1844,"completion":1844,"start":1845,"enrollment":769,"conditions":1870,"interventions":1871},[59],[1847,1848,1849,1850],[1832,1852,1853],{"trials":1873,"activeCount":69},[],{"trials":1875,"activeCount":69},[],{"trials":1877,"activeCount":69},[],{"intervention":1879,"totalTrials":185,"cells":1880},"deglycosylated ricin A chain-conjugated anti-CD19\u002Fanti-CD22 immunotoxins",{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1907,"PHASE3":1909,"PHASE4":1911,"NA":1913},{"trials":1882,"activeCount":69},[],{"trials":1884,"activeCount":69},[1885,1895],{"nctId":1886,"briefTitle":1887,"status":304,"phases":1888,"primaryCompletion":1889,"completion":1890,"start":1891,"enrollment":9,"conditions":1892,"interventions":1894},"NCT00450944","Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia",[58],"2008-10-27","2010-04-01","2006-02-22",[1893],"Leukemia",[1879],{"nctId":1896,"briefTitle":1897,"status":172,"phases":1898,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":349,"conditions":1901,"interventions":1904},"NCT01408160","Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia",[58],"2018-06-26","2013-04",[1902,1903],"Adult B Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia",[1905,1906],"Cytarabine","Deglycosylated Ricin A Chain-Conjugated Anti-CD19\u002FAnti-CD22 Immunotoxins",{"trials":1908,"activeCount":69},[],{"trials":1910,"activeCount":69},[],{"trials":1912,"activeCount":69},[],{"trials":1914,"activeCount":69},[],{"intervention":1916,"totalTrials":65,"cells":1917},"Sitagliptin and insulin\u002Fnovolog via CL",{"EARLY_PHASE1":1918,"PHASE1":1920,"PHASE2":1930,"PHASE3":1932,"PHASE4":1934,"NA":1936},{"trials":1919,"activeCount":69},[],{"trials":1921,"activeCount":69},[1922],{"nctId":1923,"briefTitle":1924,"status":304,"phases":1925,"primaryCompletion":1027,"completion":1027,"start":1926,"enrollment":1927,"conditions":1928,"interventions":1929},"NCT02328040","Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop",[58],"2014-09",17,[177],[1916],{"trials":1931,"activeCount":69},[],{"trials":1933,"activeCount":69},[],{"trials":1935,"activeCount":69},[],{"trials":1937,"activeCount":69},[],{"intervention":1939,"totalTrials":65,"cells":1940},"BMS-247550",{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1956,"PHASE3":1958,"PHASE4":1960,"NA":1962},{"trials":1942,"activeCount":69},[],{"trials":1944,"activeCount":69},[1945],{"nctId":1946,"briefTitle":1947,"status":304,"phases":1948,"primaryCompletion":1949,"completion":1949,"start":1950,"enrollment":1951,"conditions":1952,"interventions":1955},"NCT00005807","Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer",[58],"2004-08","2000-07",40,[27,1953,1954],"Ovarian Cancer","Unspecified Adult Solid Tumor, Protocol Specific",[1939],{"trials":1957,"activeCount":69},[],{"trials":1959,"activeCount":69},[],{"trials":1961,"activeCount":69},[],{"trials":1963,"activeCount":69},[],{"intervention":1905,"totalTrials":65,"cells":1965},{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1967,"activeCount":69},[],{"trials":1969,"activeCount":69},[1970],{"nctId":1896,"briefTitle":1897,"status":172,"phases":1971,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":349,"conditions":1972,"interventions":1973},[58],[1902,1903],[1905,1906],{"trials":1975,"activeCount":69},[],{"trials":1977,"activeCount":69},[],{"trials":1979,"activeCount":69},[],{"trials":1981,"activeCount":69},[],{"intervention":1983,"totalTrials":65,"cells":1984},"153Sm-DOTMP",{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":2003,"PHASE3":2005,"PHASE4":2007,"NA":2009},{"trials":1986,"activeCount":69},[],{"trials":1988,"activeCount":69},[1989],{"nctId":1990,"briefTitle":1991,"status":148,"phases":1992,"primaryCompletion":1993,"completion":1994,"start":1995,"enrollment":69,"conditions":1996,"interventions":1999},"NCT03612466","A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy",[58],"2023-01","2024-09","2022-08",[1997,1998],"Osteosarcoma","Bone Metastases",[1983,2000,2001,2002],"Calcium Carbonate","Mozobil","Neupogen Injectable Product",{"trials":2004,"activeCount":69},[],{"trials":2006,"activeCount":69},[],{"trials":2008,"activeCount":69},[],{"trials":2010,"activeCount":69},[],{"intervention":2000,"totalTrials":65,"cells":2012},{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2021,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2014,"activeCount":69},[],{"trials":2016,"activeCount":69},[2017],{"nctId":1990,"briefTitle":1991,"status":148,"phases":2018,"primaryCompletion":1993,"completion":1994,"start":1995,"enrollment":69,"conditions":2019,"interventions":2020},[58],[1997,1998],[1983,2000,2001,2002],{"trials":2022,"activeCount":69},[],{"trials":2024,"activeCount":69},[],{"trials":2026,"activeCount":69},[],{"trials":2028,"activeCount":69},[],{"intervention":2001,"totalTrials":65,"cells":2030},{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2039,"PHASE3":2041,"PHASE4":2043,"NA":2045},{"trials":2032,"activeCount":69},[],{"trials":2034,"activeCount":69},[2035],{"nctId":1990,"briefTitle":1991,"status":148,"phases":2036,"primaryCompletion":1993,"completion":1994,"start":1995,"enrollment":69,"conditions":2037,"interventions":2038},[58],[1997,1998],[1983,2000,2001,2002],{"trials":2040,"activeCount":69},[],{"trials":2042,"activeCount":69},[],{"trials":2044,"activeCount":69},[],{"trials":2046,"activeCount":69},[],{"intervention":2002,"totalTrials":65,"cells":2048},{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2057,"PHASE3":2059,"PHASE4":2061,"NA":2063},{"trials":2050,"activeCount":69},[],{"trials":2052,"activeCount":69},[2053],{"nctId":1990,"briefTitle":1991,"status":148,"phases":2054,"primaryCompletion":1993,"completion":1994,"start":1995,"enrollment":69,"conditions":2055,"interventions":2056},[58],[1997,1998],[1983,2000,2001,2002],{"trials":2058,"activeCount":69},[],{"trials":2060,"activeCount":69},[],{"trials":2062,"activeCount":69},[],{"trials":2064,"activeCount":69},[],{"intervention":2066,"totalTrials":65,"cells":2067},"TDF Intravaginal Ring",{"EARLY_PHASE1":2068,"PHASE1":2070,"PHASE2":2080,"PHASE3":2082,"PHASE4":2084,"NA":2086},{"trials":2069,"activeCount":69},[],{"trials":2071,"activeCount":69},[2072],{"nctId":2073,"briefTitle":2074,"status":304,"phases":2075,"primaryCompletion":2076,"completion":2076,"start":2077,"enrollment":8,"conditions":2078,"interventions":2079},"NCT02006264","Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring",[58],"2014-11-06","2013-11-19",[21],[2066],{"trials":2081,"activeCount":69},[],{"trials":2083,"activeCount":69},[],{"trials":2085,"activeCount":69},[],{"trials":2087,"activeCount":69},[],{"intervention":2089,"totalTrials":65,"cells":2090},"Dopamine",{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2101,"PHASE3":2103,"PHASE4":2105,"NA":2107},{"trials":2092,"activeCount":69},[],{"trials":2094,"activeCount":69},[2095],{"nctId":2096,"briefTitle":2097,"status":304,"phases":2098,"primaryCompletion":1027,"completion":1027,"start":1028,"enrollment":230,"conditions":2099,"interventions":2100},"NCT02053935","Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects",[58],[353,352],[2089],{"trials":2102,"activeCount":69},[],{"trials":2104,"activeCount":69},[],{"trials":2106,"activeCount":69},[],{"trials":2108,"activeCount":69},[],{"intervention":2110,"totalTrials":65,"cells":2111},"Midazolam Hydrochloride",{"EARLY_PHASE1":2112,"PHASE1":2114,"PHASE2":2131,"PHASE3":2133,"PHASE4":2135,"NA":2137},{"trials":2113,"activeCount":69},[],{"trials":2115,"activeCount":69},[2116],{"nctId":2117,"briefTitle":2118,"status":304,"phases":2119,"primaryCompletion":2120,"completion":2120,"start":2121,"enrollment":2122,"conditions":2123,"interventions":2126},"NCT06867068","Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery",[58],"2024-06-10","2016-10-04",73,[2124,2125],"Anesthesia","Tooth Extraction",[2110,2127,2128,2129,2130],"Fentanyl","Ketamine","Propofol","Nitrous oxide",{"trials":2132,"activeCount":69},[],{"trials":2134,"activeCount":69},[],{"trials":2136,"activeCount":69},[],{"trials":2138,"activeCount":69},[],{"intervention":2127,"totalTrials":65,"cells":2140},{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2149,"PHASE3":2151,"PHASE4":2153,"NA":2155},{"trials":2142,"activeCount":69},[],{"trials":2144,"activeCount":69},[2145],{"nctId":2117,"briefTitle":2118,"status":304,"phases":2146,"primaryCompletion":2120,"completion":2120,"start":2121,"enrollment":2122,"conditions":2147,"interventions":2148},[58],[2124,2125],[2110,2127,2128,2129,2130],{"trials":2150,"activeCount":69},[],{"trials":2152,"activeCount":69},[],{"trials":2154,"activeCount":69},[],{"trials":2156,"activeCount":69},[],{"intervention":2128,"totalTrials":65,"cells":2158},{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2167,"PHASE3":2169,"PHASE4":2171,"NA":2173},{"trials":2160,"activeCount":69},[],{"trials":2162,"activeCount":69},[2163],{"nctId":2117,"briefTitle":2118,"status":304,"phases":2164,"primaryCompletion":2120,"completion":2120,"start":2121,"enrollment":2122,"conditions":2165,"interventions":2166},[58],[2124,2125],[2110,2127,2128,2129,2130],{"trials":2168,"activeCount":69},[],{"trials":2170,"activeCount":69},[],{"trials":2172,"activeCount":69},[],{"trials":2174,"activeCount":69},[],{"intervention":2129,"totalTrials":65,"cells":2176},{"EARLY_PHASE1":2177,"PHASE1":2179,"PHASE2":2185,"PHASE3":2187,"PHASE4":2189,"NA":2191},{"trials":2178,"activeCount":69},[],{"trials":2180,"activeCount":69},[2181],{"nctId":2117,"briefTitle":2118,"status":304,"phases":2182,"primaryCompletion":2120,"completion":2120,"start":2121,"enrollment":2122,"conditions":2183,"interventions":2184},[58],[2124,2125],[2110,2127,2128,2129,2130],{"trials":2186,"activeCount":69},[],{"trials":2188,"activeCount":69},[],{"trials":2190,"activeCount":69},[],{"trials":2192,"activeCount":69},[],{"intervention":2130,"totalTrials":65,"cells":2194},{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2203,"PHASE3":2205,"PHASE4":2207,"NA":2209},{"trials":2196,"activeCount":69},[],{"trials":2198,"activeCount":69},[2199],{"nctId":2117,"briefTitle":2118,"status":304,"phases":2200,"primaryCompletion":2120,"completion":2120,"start":2121,"enrollment":2122,"conditions":2201,"interventions":2202},[58],[2124,2125],[2110,2127,2128,2129,2130],{"trials":2204,"activeCount":69},[],{"trials":2206,"activeCount":69},[],{"trials":2208,"activeCount":69},[],{"trials":2210,"activeCount":69},[],{"intervention":2212,"totalTrials":65,"cells":2213},"Azacitidine",{"EARLY_PHASE1":2214,"PHASE1":2216,"PHASE2":2226,"PHASE3":2228,"PHASE4":2230,"NA":2232},{"trials":2215,"activeCount":69},[],{"trials":2217,"activeCount":69},[2218],{"nctId":2219,"briefTitle":2220,"status":304,"phases":2221,"primaryCompletion":2222,"completion":2222,"start":2223,"enrollment":19,"conditions":2224,"interventions":2225},"NCT02009436","Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer",[58],"2018-07-18","2015-02-09",[964,966],[2212],{"trials":2227,"activeCount":69},[],{"trials":2229,"activeCount":69},[],{"trials":2231,"activeCount":69},[],{"trials":2233,"activeCount":69},[],{"intervention":2235,"totalTrials":65,"cells":2236},"SULT Allosteric Inhibition",{"EARLY_PHASE1":2237,"PHASE1":2248,"PHASE2":2250,"PHASE3":2252,"PHASE4":2254,"NA":2256},{"trials":2238,"activeCount":69},[2239],{"nctId":2240,"briefTitle":2241,"status":304,"phases":2242,"primaryCompletion":2243,"completion":2243,"start":2244,"enrollment":65,"conditions":2245,"interventions":2247},"NCT03383133","Studies of Sulfur Metabolism in Humans",[57],"2023-02-02","2018-01-11",[2246],"Metabolic Side Effects of Drugs",[2235],{"trials":2249,"activeCount":69},[],{"trials":2251,"activeCount":69},[],{"trials":2253,"activeCount":69},[],{"trials":2255,"activeCount":69},[],{"trials":2257,"activeCount":69},[],{"intervention":2259,"totalTrials":65,"cells":2260},"Aldesleukin",{"EARLY_PHASE1":2261,"PHASE1":2278,"PHASE2":2280,"PHASE3":2282,"PHASE4":2284,"NA":2286},{"trials":2262,"activeCount":69},[2263],{"nctId":2264,"briefTitle":2265,"status":172,"phases":2266,"primaryCompletion":2267,"completion":2268,"start":2269,"enrollment":137,"conditions":2270,"interventions":2274},"NCT02774291","Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes",[57],"2020-07-01","2020-08-04","2017-04-20",[2271,2272,2273],"HLA-A2 Positive Cells Present","Metastatic Malignant Neoplasm","Metastatic Malignant Neoplasm in the Brain",[2259,2275,1788,2276,2277],"Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes","Filgrastim","Fludarabine Phosphate",{"trials":2279,"activeCount":69},[],{"trials":2281,"activeCount":69},[],{"trials":2283,"activeCount":69},[],{"trials":2285,"activeCount":69},[],{"trials":2287,"activeCount":69},[],{"intervention":2275,"totalTrials":65,"cells":2289},{"EARLY_PHASE1":2290,"PHASE1":2296,"PHASE2":2298,"PHASE3":2300,"PHASE4":2302,"NA":2304},{"trials":2291,"activeCount":69},[2292],{"nctId":2264,"briefTitle":2265,"status":172,"phases":2293,"primaryCompletion":2267,"completion":2268,"start":2269,"enrollment":137,"conditions":2294,"interventions":2295},[57],[2271,2272,2273],[2259,2275,1788,2276,2277],{"trials":2297,"activeCount":69},[],{"trials":2299,"activeCount":69},[],{"trials":2301,"activeCount":69},[],{"trials":2303,"activeCount":69},[],{"trials":2305,"activeCount":69},[],{"intervention":2277,"totalTrials":65,"cells":2307},{"EARLY_PHASE1":2308,"PHASE1":2314,"PHASE2":2316,"PHASE3":2318,"PHASE4":2320,"NA":2322},{"trials":2309,"activeCount":69},[2310],{"nctId":2264,"briefTitle":2265,"status":172,"phases":2311,"primaryCompletion":2267,"completion":2268,"start":2269,"enrollment":137,"conditions":2312,"interventions":2313},[57],[2271,2272,2273],[2259,2275,1788,2276,2277],{"trials":2315,"activeCount":69},[],{"trials":2317,"activeCount":69},[],{"trials":2319,"activeCount":69},[],{"trials":2321,"activeCount":69},[],{"trials":2323,"activeCount":69},[],{"intervention":1785,"totalTrials":28,"cells":2325},{"EARLY_PHASE1":2326,"PHASE1":2328,"PHASE2":2330,"PHASE3":2375,"PHASE4":2377,"NA":2379},{"trials":2327,"activeCount":69},[],{"trials":2329,"activeCount":69},[],{"trials":2331,"activeCount":69},[2332,2349,2360,2364],{"nctId":2333,"briefTitle":2334,"status":172,"phases":2335,"primaryCompletion":2336,"completion":2336,"start":2337,"enrollment":217,"conditions":2338,"interventions":2348},"NCT01041027","Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer",[59],"2019-10-01","2009-01-16",[2339,2340,2341,2342,2343,2344,2345,2346,2347],"Endometrial Adenocarcinoma","Stage IA Uterine Corpus Cancer","Stage IB Uterine Corpus Cancer","Stage II Uterine Corpus Cancer","Stage IIIA Uterine Corpus Cancer","Stage IIIB Uterine Corpus Cancer","Stage IIIC Uterine Corpus Cancer","Stage IVA Uterine Corpus Cancer","Stage IVB Uterine Corpus Cancer",[1785,1007],{"nctId":2350,"briefTitle":2351,"status":304,"phases":2352,"primaryCompletion":657,"completion":2353,"start":2354,"enrollment":2355,"conditions":2356,"interventions":2359},"NCT02073968","PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer",[59],"2020-11","2013-07",35,[2273,964,2357,2358,976,965,966],"Stage IIA Non-Small Cell Lung Carcinoma","Stage IIB Non-Small Cell Lung Carcinoma",[1007,1785],{"nctId":1778,"briefTitle":1779,"status":304,"phases":2361,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":1353,"conditions":2362,"interventions":2363},[58,59],[27],[1769,1785,1786,1787,1788],{"nctId":2365,"briefTitle":2366,"status":172,"phases":2367,"primaryCompletion":363,"completion":2368,"start":2369,"enrollment":34,"conditions":2370,"interventions":2374},"NCT02112552","Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer",[59],"2017-12-01","2014-04-10",[2371,2343,2344,2372,2373,2346,2347],"Endometrial Serous Adenocarcinoma","Stage IIIC1 Uterine Corpus Cancer","Stage IIIC2 Uterine Corpus Cancer",[1785,1007],{"trials":2376,"activeCount":69},[],{"trials":2378,"activeCount":69},[],{"trials":2380,"activeCount":69},[2381,2397],{"nctId":2382,"briefTitle":2383,"status":172,"phases":2384,"primaryCompletion":2385,"completion":2385,"start":2386,"enrollment":217,"conditions":2387,"interventions":2394},"NCT01897441","Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer",[62],"2023-10-25","2013-06",[2388,2389,2390,2391,2392,2393],"Stage IIA Breast Cancer","Stage IIB Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Stage IV Breast Cancer",[1788,2395,1785,1786,2396],"Doxorubicin Hydrochloride","Endocrine therapy",{"nctId":2398,"briefTitle":2399,"status":172,"phases":2400,"primaryCompletion":2401,"completion":2401,"start":2402,"enrollment":2403,"conditions":2404,"interventions":2416},"NCT01367301","Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer",[62],"2018-08-15","2011-07-08",14,[2405,2406,2407,2408,2409,2410,2411,2412,2413,2414,2415],"Stage IA Uterine Sarcoma","Stage IB Uterine Sarcoma","Stage IC Uterine Sarcoma","Stage IIA Uterine Sarcoma","Stage IIB Uterine Sarcoma","Stage IIIA Uterine Sarcoma","Stage IIIB Uterine Sarcoma","Stage IIIC Uterine Sarcoma","Stage IVA Uterine Sarcoma","Stage IVB Uterine Sarcoma","Uterine Carcinosarcoma",[2417,2418],"paclitaxel","carboplatin",{"intervention":1007,"totalTrials":31,"cells":2420},{"EARLY_PHASE1":2421,"PHASE1":2423,"PHASE2":2425,"PHASE3":2443,"PHASE4":2445,"NA":2447},{"trials":2422,"activeCount":69},[],{"trials":2424,"activeCount":69},[],{"trials":2426,"activeCount":69},[2427,2431,2435,2439],{"nctId":2333,"briefTitle":2334,"status":172,"phases":2428,"primaryCompletion":2336,"completion":2336,"start":2337,"enrollment":217,"conditions":2429,"interventions":2430},[59],[2339,2340,2341,2342,2343,2344,2345,2346,2347],[1785,1007],{"nctId":2350,"briefTitle":2351,"status":304,"phases":2432,"primaryCompletion":657,"completion":2353,"start":2354,"enrollment":2355,"conditions":2433,"interventions":2434},[59],[2273,964,2357,2358,976,965,966],[1007,1785],{"nctId":997,"briefTitle":998,"status":304,"phases":2436,"primaryCompletion":508,"completion":1000,"start":1001,"enrollment":308,"conditions":2437,"interventions":2438},[59],[1003,1004,1005],[1007,968],{"nctId":2365,"briefTitle":2366,"status":172,"phases":2440,"primaryCompletion":363,"completion":2368,"start":2369,"enrollment":34,"conditions":2441,"interventions":2442},[59],[2371,2343,2344,2372,2373,2346,2347],[1785,1007],{"trials":2444,"activeCount":69},[],{"trials":2446,"activeCount":69},[],{"trials":2448,"activeCount":69},[2449],{"nctId":2398,"briefTitle":2399,"status":172,"phases":2450,"primaryCompletion":2401,"completion":2401,"start":2402,"enrollment":2403,"conditions":2451,"interventions":2452},[62],[2405,2406,2407,2408,2409,2410,2411,2412,2413,2414,2415],[2417,2418],{"intervention":1788,"totalTrials":137,"cells":2454},{"EARLY_PHASE1":2455,"PHASE1":2461,"PHASE2":2463,"PHASE3":2469,"PHASE4":2471,"NA":2473},{"trials":2456,"activeCount":69},[2457],{"nctId":2264,"briefTitle":2265,"status":172,"phases":2458,"primaryCompletion":2267,"completion":2268,"start":2269,"enrollment":137,"conditions":2459,"interventions":2460},[57],[2271,2272,2273],[2259,2275,1788,2276,2277],{"trials":2462,"activeCount":69},[],{"trials":2464,"activeCount":69},[2465],{"nctId":1778,"briefTitle":1779,"status":304,"phases":2466,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":1353,"conditions":2467,"interventions":2468},[58,59],[27],[1769,1785,1786,1787,1788],{"trials":2470,"activeCount":69},[],{"trials":2472,"activeCount":69},[],{"trials":2474,"activeCount":69},[2475],{"nctId":2382,"briefTitle":2383,"status":172,"phases":2476,"primaryCompletion":2385,"completion":2385,"start":2386,"enrollment":217,"conditions":2477,"interventions":2478},[62],[2388,2389,2390,2391,2392,2393],[1788,2395,1785,1786,2396],{"intervention":1549,"totalTrials":185,"cells":2480},{"EARLY_PHASE1":2481,"PHASE1":2483,"PHASE2":2485,"PHASE3":2491,"PHASE4":2493,"NA":2495},{"trials":2482,"activeCount":69},[],{"trials":2484,"activeCount":69},[],{"trials":2486,"activeCount":69},[2487],{"nctId":1534,"briefTitle":1535,"status":172,"phases":2488,"primaryCompletion":1537,"completion":1537,"start":1538,"enrollment":1539,"conditions":2489,"interventions":2490},[59],[1541,1542,1543,1544],[1525,1546,1547,1548,1549],{"trials":2492,"activeCount":69},[],{"trials":2494,"activeCount":69},[],{"trials":2496,"activeCount":69},[2497],{"nctId":2498,"briefTitle":2499,"status":304,"phases":2500,"primaryCompletion":2501,"completion":2501,"start":2502,"enrollment":1273,"conditions":2503,"interventions":2506},"NCT00846482","Exploratory Study Of The ERCC-1 Gene",[62],"2018-12","2008-02",[2504,2505],"Colon Cancer","Rectal Cancer",[1549],{"intervention":2276,"totalTrials":185,"cells":2508},{"EARLY_PHASE1":2509,"PHASE1":2515,"PHASE2":2517,"PHASE3":2519,"PHASE4":2521,"NA":2523},{"trials":2510,"activeCount":69},[2511],{"nctId":2264,"briefTitle":2265,"status":172,"phases":2512,"primaryCompletion":2267,"completion":2268,"start":2269,"enrollment":137,"conditions":2513,"interventions":2514},[57],[2271,2272,2273],[2259,2275,1788,2276,2277],{"trials":2516,"activeCount":69},[],{"trials":2518,"activeCount":69},[],{"trials":2520,"activeCount":69},[],{"trials":2522,"activeCount":69},[],{"trials":2524,"activeCount":69},[2525],{"nctId":2526,"briefTitle":2527,"status":172,"phases":2528,"primaryCompletion":551,"completion":551,"start":347,"enrollment":9,"conditions":2529,"interventions":2531},"NCT01899326","Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant",[62],[2530,1848,1849,1850],"DS (Durie\u002FSalmon) Stage I Plasma Cell Myeloma",[2532,2276],"Desipramine Hydrochloride",{"intervention":1786,"totalTrials":185,"cells":2534},{"EARLY_PHASE1":2535,"PHASE1":2537,"PHASE2":2539,"PHASE3":2545,"PHASE4":2547,"NA":2549},{"trials":2536,"activeCount":69},[],{"trials":2538,"activeCount":69},[],{"trials":2540,"activeCount":69},[2541],{"nctId":1778,"briefTitle":1779,"status":304,"phases":2542,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":1353,"conditions":2543,"interventions":2544},[58,59],[27],[1769,1785,1786,1787,1788],{"trials":2546,"activeCount":69},[],{"trials":2548,"activeCount":69},[],{"trials":2550,"activeCount":69},[2551],{"nctId":2382,"briefTitle":2383,"status":172,"phases":2552,"primaryCompletion":2385,"completion":2385,"start":2386,"enrollment":217,"conditions":2553,"interventions":2554},[62],[2388,2389,2390,2391,2392,2393],[1788,2395,1785,1786,2396],{"intervention":1546,"totalTrials":185,"cells":2556},{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2567,"PHASE4":2569,"NA":2571},{"trials":2558,"activeCount":69},[],{"trials":2560,"activeCount":69},[],{"trials":2562,"activeCount":69},[2563],{"nctId":1534,"briefTitle":1535,"status":172,"phases":2564,"primaryCompletion":1537,"completion":1537,"start":1538,"enrollment":1539,"conditions":2565,"interventions":2566},[59],[1541,1542,1543,1544],[1525,1546,1547,1548,1549],{"trials":2568,"activeCount":69},[],{"trials":2570,"activeCount":69},[],{"trials":2572,"activeCount":69},[2573],{"nctId":2574,"briefTitle":2575,"status":172,"phases":2576,"primaryCompletion":2577,"completion":2577,"start":2578,"enrollment":137,"conditions":2579,"interventions":2581},"NCT01958580","Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery",[62],"2017-02-24","2013-09-17",[2405,2406,2407,2408,2409,2410,2411,2412,2413,2414,2580],"Uterine Corpus Leiomyosarcoma",[1546,2582],"Docetaxel",{"intervention":2584,"totalTrials":185,"cells":2585},"Varenicline",{"EARLY_PHASE1":2586,"PHASE1":2588,"PHASE2":2590,"PHASE3":2592,"PHASE4":2594,"NA":2606},{"trials":2587,"activeCount":69},[],{"trials":2589,"activeCount":69},[],{"trials":2591,"activeCount":69},[],{"trials":2593,"activeCount":69},[],{"trials":2595,"activeCount":69},[2596],{"nctId":2597,"briefTitle":2598,"status":304,"phases":2599,"primaryCompletion":2600,"completion":2600,"start":365,"enrollment":2601,"conditions":2602,"interventions":2605},"NCT01027754","Smoking Cessation Treatment for Methadone Maintenance Patients",[61],"2011-09",112,[2603,2604],"Smoking Cessation","Substance-Related Disorders",[2584],{"trials":2607,"activeCount":69},[2608],{"nctId":2609,"briefTitle":2610,"status":304,"phases":2611,"primaryCompletion":507,"completion":507,"start":419,"enrollment":161,"conditions":2612,"interventions":2614},"NCT01378858","Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients",[62],[579,2613],"Medication Adherence",[2584],{"intervention":2616,"totalTrials":185,"cells":2617},"melphalan",{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2622,"PHASE3":2628,"PHASE4":2630,"NA":2632},{"trials":2619,"activeCount":69},[],{"trials":2621,"activeCount":69},[],{"trials":2623,"activeCount":69},[2624],{"nctId":1841,"briefTitle":1842,"status":304,"phases":2625,"primaryCompletion":1844,"completion":1844,"start":1845,"enrollment":769,"conditions":2626,"interventions":2627},[59],[1847,1848,1849,1850],[1832,1852,1853],{"trials":2629,"activeCount":69},[],{"trials":2631,"activeCount":69},[],{"trials":2633,"activeCount":69},[2634],{"nctId":2635,"briefTitle":2636,"status":148,"phases":2637,"primaryCompletion":2638,"completion":2638,"start":2639,"enrollment":69,"conditions":2640,"interventions":2652},"NCT02507076","Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma",[62],"2014-07","2012-04",[2641,2642,2643,2644,2645,2646,2647,2648,2649,2650,2651],"Basal Cell Carcinoma of the Skin","Eccrine Carcinoma of the Skin","Recurrent Adult Soft Tissue Sarcoma","Recurrent Melanoma","Recurrent Skin Cancer","Squamous Cell Carcinoma of the Skin","Stage III Adult Soft Tissue Sarcoma","Stage IIIB Melanoma","Stage IIIC Melanoma","Stage IV Adult Soft Tissue Sarcoma","Stage IV Melanoma",[2653,2616],"isolated limb perfusion",{"intervention":2655,"totalTrials":65,"cells":2656},"Pancreatic Clamp",{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2661,"PHASE3":2663,"PHASE4":2665,"NA":2667},{"trials":2658,"activeCount":69},[],{"trials":2660,"activeCount":69},[],{"trials":2662,"activeCount":69},[],{"trials":2664,"activeCount":69},[],{"trials":2666,"activeCount":69},[],{"trials":2668,"activeCount":69},[2669],{"nctId":2670,"briefTitle":2671,"status":304,"phases":2672,"primaryCompletion":657,"completion":657,"start":394,"enrollment":161,"conditions":2673,"interventions":2676},"NCT02987335","Metabolic Characteristics of Lean Diabetes in Rural and Semi-urban India and in the United States",[],[2674,2675],"Malnutrition; Diabetes","Diabetes",[2655],{"intervention":2532,"totalTrials":65,"cells":2678},{"EARLY_PHASE1":2679,"PHASE1":2681,"PHASE2":2683,"PHASE3":2685,"PHASE4":2687,"NA":2689},{"trials":2680,"activeCount":69},[],{"trials":2682,"activeCount":69},[],{"trials":2684,"activeCount":69},[],{"trials":2686,"activeCount":69},[],{"trials":2688,"activeCount":69},[],{"trials":2690,"activeCount":69},[2691],{"nctId":2526,"briefTitle":2527,"status":172,"phases":2692,"primaryCompletion":551,"completion":551,"start":347,"enrollment":9,"conditions":2693,"interventions":2694},[62],[2530,1848,1849,1850],[2532,2276],{"intervention":2395,"totalTrials":65,"cells":2696},{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2701,"PHASE3":2703,"PHASE4":2705,"NA":2707},{"trials":2698,"activeCount":69},[],{"trials":2700,"activeCount":69},[],{"trials":2702,"activeCount":69},[],{"trials":2704,"activeCount":69},[],{"trials":2706,"activeCount":69},[],{"trials":2708,"activeCount":69},[2709],{"nctId":2382,"briefTitle":2383,"status":172,"phases":2710,"primaryCompletion":2385,"completion":2385,"start":2386,"enrollment":217,"conditions":2711,"interventions":2712},[62],[2388,2389,2390,2391,2392,2393],[1788,2395,1785,1786,2396],{"intervention":2396,"totalTrials":65,"cells":2714},{"EARLY_PHASE1":2715,"PHASE1":2717,"PHASE2":2719,"PHASE3":2721,"PHASE4":2723,"NA":2725},{"trials":2716,"activeCount":69},[],{"trials":2718,"activeCount":69},[],{"trials":2720,"activeCount":69},[],{"trials":2722,"activeCount":69},[],{"trials":2724,"activeCount":69},[],{"trials":2726,"activeCount":69},[2727],{"nctId":2382,"briefTitle":2383,"status":172,"phases":2728,"primaryCompletion":2385,"completion":2385,"start":2386,"enrollment":217,"conditions":2729,"interventions":2730},[62],[2388,2389,2390,2391,2392,2393],[1788,2395,1785,1786,2396],{"intervention":2732,"totalTrials":65,"cells":2733},"Local anesthetic",{"EARLY_PHASE1":2734,"PHASE1":2736,"PHASE2":2738,"PHASE3":2740,"PHASE4":2742,"NA":2744},{"trials":2735,"activeCount":69},[],{"trials":2737,"activeCount":69},[],{"trials":2739,"activeCount":69},[],{"trials":2741,"activeCount":69},[],{"trials":2743,"activeCount":69},[],{"trials":2745,"activeCount":69},[2746],{"nctId":2747,"briefTitle":2748,"status":304,"phases":2749,"primaryCompletion":2750,"completion":2751,"start":2752,"enrollment":2753,"conditions":2754,"interventions":2756},"NCT04549051","Percutaneous Interruption of the Coracohumeral Ligament for the Treatment of Frozen Shoulder",[62],"2022-03-16","2023-01-19","2020-11-17",46,[2755],"Adhesive Capsulitis",[2732],{"intervention":2758,"totalTrials":65,"cells":2759},"morphine",{"EARLY_PHASE1":2760,"PHASE1":2762,"PHASE2":2764,"PHASE3":2766,"PHASE4":2768,"NA":2770},{"trials":2761,"activeCount":69},[],{"trials":2763,"activeCount":69},[],{"trials":2765,"activeCount":69},[],{"trials":2767,"activeCount":69},[],{"trials":2769,"activeCount":69},[],{"trials":2771,"activeCount":69},[2772],{"nctId":2773,"briefTitle":2774,"status":304,"phases":2775,"primaryCompletion":2776,"completion":2776,"start":2777,"enrollment":2778,"conditions":2779,"interventions":2780},"NCT00910208","Safety and Efficacy of Patient Controlled Analgesia in the Emergency Department",[62],"2010-06","2009-04",211,[25],[2758],{"intervention":2582,"totalTrials":65,"cells":2782},{"EARLY_PHASE1":2783,"PHASE1":2785,"PHASE2":2787,"PHASE3":2789,"PHASE4":2791,"NA":2793},{"trials":2784,"activeCount":69},[],{"trials":2786,"activeCount":69},[],{"trials":2788,"activeCount":69},[],{"trials":2790,"activeCount":69},[],{"trials":2792,"activeCount":69},[],{"trials":2794,"activeCount":69},[2795],{"nctId":2574,"briefTitle":2575,"status":172,"phases":2796,"primaryCompletion":2577,"completion":2577,"start":2578,"enrollment":137,"conditions":2797,"interventions":2798},[62],[2405,2406,2407,2408,2409,2410,2411,2412,2413,2414,2580],[1546,2582],{"intervention":2653,"totalTrials":65,"cells":2800},{"EARLY_PHASE1":2801,"PHASE1":2803,"PHASE2":2805,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2802,"activeCount":69},[],{"trials":2804,"activeCount":69},[],{"trials":2806,"activeCount":69},[],{"trials":2808,"activeCount":69},[],{"trials":2810,"activeCount":69},[],{"trials":2812,"activeCount":69},[2813],{"nctId":2635,"briefTitle":2636,"status":148,"phases":2814,"primaryCompletion":2638,"completion":2638,"start":2639,"enrollment":69,"conditions":2815,"interventions":2816},[62],[2641,2642,2643,2644,2645,2646,2647,2648,2649,2650,2651],[2653,2616]]